# GABBR2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *GABBR2* gene encodes the GABAB receptor subunit 2 (GB2), an essential component of the metabotropic GABAB receptor complex, which mediates slow, inhibitory neurotransmission in the central nervous system by coupling to Gi/o proteins to modulate adenylyl cyclase, voltage-gated calcium channels, and inwardly rectifying potassium channels.
- Pathogenic variants in *GABBR2* are directly linked to severe neurodevelopmental disorders, including early-infantile epileptic encephalopathy 59 (EIEE59), Rett syndrome-like phenotypes, autism spectrum disorder (ASD), and intellectual disability, often resulting from loss-of-function mechanisms due to impaired receptor trafficking or G-protein coupling.
- The GABBR2 protein exhibits a complex domain architecture, including a Venus flytrap (VFT) domain critical for heterodimerization, a cysteine-rich domain (CRD) for signal transduction, a seven-transmembrane (7TM) domain for G-protein coupling, and an intracellular C-terminal domain (CTD) involved in protein interactions and receptor stabilization.
- Beyond neurological conditions, *GABBR2* expression is epigenetically regulated, with promoter hypermethylation implicated in cancer (e.g., lung adenocarcinoma response to erlotinib) and its signaling pathways are involved in substance use disorders, migraine pathophysiology, and Alzheimer's disease.
- Therapeutic strategies targeting GABAB receptors include orthosteric agonists like baclofen, positive allosteric modulators (PAMs) that enhance receptor signaling (e.g., GS39783, rac-BHFF) for conditions like epilepsy and anxiety, and antagonists primarily used as research tools.
- Viral microRNAs, such as those encoded by Herpes Simplex Virus Type 1 (HSV-1), can target *GABBR2*, potentially modulating GABAergic signaling in infected neurons and contributing to neurological complications like seizures in viral encephalitis.

---

## Executive Summary & Key Metadata

The *GABBR2* gene encodes the gamma-aminobutyric acid type B receptor subunit 2 (GABABR2, GB2), an obligatory component of the metabotropic GABAB receptor (GABABR) complex. GABABRs mediate slow, prolonged inhibitory neurotransmission in the central nervous system (CNS) and modulate neurotransmitter release at both pre- and postsynaptic terminals. Unlike ionotropic GABAA receptors that form chloride-permeable channels, GABABRs are class C G-protein-coupled receptors (GPCRs) that signal through heterotrimeric Gi/o proteins to regulate adenylyl cyclase activity, voltage-gated calcium channels (VGCCs), and inwardly rectifying potassium channels (GIRKs). The GB2 subunit does not bind GABA directly; instead, it is essential for trafficking the heterodimer to the cell surface, coupling to G-proteins, and mediating downstream effector modulation. Pathogenic variants in *GABBR2* are associated with a spectrum of neurodevelopmental and epileptic disorders, including early-infantile epileptic encephalopathy 59 (EIEE59), Rett syndrome-like phenotypes, autism spectrum disorder (ASD), and intellectual disability. Beyond neurology, *GABBR2* expression and epigenetic regulation have been implicated in multiple cancer types, substance use disorders, and metabolic conditions.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | GABBR2 |
| UniProt Accession | O75899 |
| Representative PDB ID | 7C7S (full-length human GABAB receptor heterodimer) |
| Chromosomal Locus | 9q22.33 |
| Primary Molecular Function | G-protein-coupled receptor signaling; GABAB receptor subunit 2; Gi/o activation; adenylyl cyclase inhibition; GIRK channel activation; VGCC inhibition |
| Disease & Pathology Associations | Early-infantile epileptic encephalopathy 59 (EIEE59; OMIM #617904), Rett syndrome-like phenotype, autism spectrum disorder, intellectual disability, schizophrenia, nicotine/alcohol dependence, migraine, Alzheimer's disease, prostate cancer, lung adenocarcinoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

*GABBR2* is located on the long arm of chromosome 9 at cytogenetic band 9q22.33. The gene spans approximately 285 kilobases (kb) of genomic DNA on the plus strand (GRCh38/hg38: chr9:98,288,240–98,573,267). The genomic architecture is complex, comprising at least 19 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 19. The coding sequence (CDS) is 2,715 nucleotides in length, encoding a protein of 941 amino acids with a predicted molecular mass of approximately 106 kDa (before post-translational modification). The 5' untranslated region (UTR) is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that may regulate translational efficiency in a cell-type-specific manner. The 3' UTR spans ~4.5 kb and contains numerous binding sites for microRNAs (miRNAs), including miR-31-3p, which has been experimentally validated as a direct regulator of *GABBR2* expression in prostate cancer [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *GABBR2* lacks a canonical TATA box but contains a high-density CpG island spanning from approximately −800 bp to +200 bp relative to the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated epigenetic silencing. In a genome-wide DNA methylation analysis of EGFR 19-deletion lung adenocarcinoma, *GABBR2* was identified as a novel epigenetic target whose promoter methylation status correlated with response to induction erlotinib treatment [<a href="#ref-2">2</a>]. Hypermethylation of the *GABBR2* promoter resulted in reduced transcript expression, and demethylation agents restored expression, indicating that this locus is subject to dynamic epigenetic control in cancer.

Several transcription factor binding sites (TFBS) have been predicted and partially validated within the proximal promoter, including binding motifs for SP1, EGR1, and CREB. The presence of a cAMP-responsive element (CRE) is consistent with the observation that *GABBR2* expression can be modulated by agents that alter intracellular cAMP levels, such as forskolin and phosphodiesterase inhibitors. Additionally, a neuron-restrictive silencer element (NRSE/RE-1) has been identified in intron 1, which binds the RE-1 silencing transcription factor (REST). REST-mediated repression of *GABBR2* in non-neuronal tissues contributes to its predominantly neuronal expression pattern. In the context of glioblastoma, chromatin remodelling studies have identified *GABBR2* as part of the epigenetically regulated landscape, with alterations in histone acetylation and chromatin accessibility at this locus affecting downstream signaling pathways [<a href="#ref-3">3</a>].

### 1.3 Enhancer Elements and Long-Range Chromatin Interactions

Chromatin conformation capture (Hi-C) data from human brain tissues indicate that the *GABBR2* promoter engages in long-range interactions with several putative enhancer elements located up to 500 kb upstream and downstream of the TSS. One such enhancer, located in an intergenic region between *GABBR2* and the neighboring gene *SEMA4D*, shows DNase I hypersensitivity and H3K27ac marks specifically in cortical neurons. These enhancer-promoter interactions are dynamically regulated during neuronal differentiation, with a marked increase in interaction frequency upon differentiation of induced pluripotent stem cells (iPSCs) into mature neurons. This regulatory complexity may explain the tissue-specific and developmental stage-specific expression of *GABBR2*.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *GABBR2* generates multiple transcript variants. The predominant isoform in the adult brain is the full-length 941-amino-acid protein (isoform 1). A second isoform, lacking exon 6, produces a protein with an in-frame deletion of 30 amino acids within the extracellular Venus flytrap (VFT) domain. This isoform, termed GABBR2-ΔVFT, shows impaired heterodimerization with GABBR1 and reduced cell-surface expression, suggesting that exon 6 is critical for proper protein folding and subunit assembly. A third isoform, generated by alternative splicing of exon 19, results in a truncated protein lacking the C-terminal coiled-coil domain. This truncated isoform exerts a dominant-negative effect when co-expressed with the full-length protein, sequestering GABBR1 in the endoplasmic reticulum and preventing surface trafficking. The relative abundance of these isoforms varies across brain regions and developmental stages, with the full-length isoform being most abundant in the adult cortex and hippocampus.

### 1.5 Cross-Species Conservation

*GABBR2* is highly conserved across vertebrates. The mouse ortholog *Gabbr2* shares 98.5% amino acid identity with the human protein. A floxed *Gabbr2* mouse model has been developed, allowing for widespread conditional disruption of the gene; germline knockout recapitulates the phenotype of global *Gabbr2* knockout mice, including severe neurological dysfunction, growth retardation, and premature death [<a href="#ref-4">4</a>]. The high degree of conservation underscores the non-redundant function of this gene in mammalian physiology.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

GABBR2 is a class C GPCR characterized by a large extracellular domain (ECD), a seven-transmembrane (7TM) helical bundle, and an intracellular C-terminal domain. The protein is synthesized as a precursor with a cleavable signal peptide (residues 1–23). The mature protein consists of:

- **Venus flytrap (VFT) domain**: residues 24–450
- **Cysteine-rich domain (CRD)**: residues 451–530
- **Seven-transmembrane domain (7TM)**: residues 531–800
- **Intracellular C-terminal domain (CTD)**: residues 801–941

### 2.2 Venus Flytrap (VFT) Domain

The VFT domain of GABBR2 adopts a bilobed clamshell architecture characteristic of bacterial periplasmic binding proteins. Unlike the VFT domain of GABBR1, which contains the orthosteric GABA binding site, the VFT domain of GABBR2 does not bind GABA. Instead, it serves a structural role, stabilizing the heterodimeric interface with GABBR1. The VFT domain of GABBR2 contains a critical intramolecular disulfide bond between Cys129 and Cys226 that is required for proper folding. Mutations that disrupt this disulfide bond, such as C129Y, result in ER retention and loss of function. The VFT domain also contains N-linked glycosylation sites at Asn98, Asn201, and Asn342; glycosylation at these sites is required for cell-surface expression and receptor function.

### 2.3 Cysteine-Rich Domain (CRD)

The CRD connects the VFT domain to the 7TM domain and contains nine conserved cysteine residues that form a network of disulfide bonds. This domain is thought to transduce conformational changes from the VFT domain to the 7TM domain upon ligand binding to the GABBR1 subunit. The CRD of GABBR2 also contributes to the dimerization interface, with specific residues in this region forming hydrogen bonds with the corresponding CRD of GABBR1.

### 2.4 Seven-Transmembrane (7TM) Domain

The 7TM domain of GABBR2 is the primary G-protein-coupling interface. Unlike rhodopsin-like class A GPCRs, the 7TM domain of class C GPCRs has a more open conformation, with a larger intracellular cavity that accommodates the C-terminal tail of the Gα subunit. The 7TM domain of GABBR2 contains several residues critical for G-protein coupling, including Asp720, Arg724, and Glu728 in transmembrane helix 6 (TM6). Mutations in this region, such as the pathogenic variant A789V, disrupt G-protein coupling and lead to loss of receptor function [<a href="#ref-1">1</a>]. The 7TM domain also contains the binding site for positive allosteric modulators (PAMs) such as rac-BHFF and GS39783, which enhance receptor signaling without directly activating the receptor.

### 2.5 Intracellular C-Terminal Domain (CTD)

The CTD of GABBR2 is essential for heterodimerization with GABBR1. It contains a coiled-coil motif spanning residues 860–920 that forms a parallel coiled-coil with the corresponding motif in the GABBR1 CTD. This coiled-coil interaction is required for the mutual masking of endoplasmic reticulum (ER) retention signals present in both subunits. The CTD also contains multiple phosphorylation sites, including Ser867, Ser892, and Ser923, which are substrates for protein kinase C (PKC) and casein kinase 2 (CK2). Phosphorylation of these residues modulates receptor desensitization and internalization. Additionally, the CTD interacts with several scaffolding proteins, including 14-3-3 proteins, which stabilize the receptor at the plasma membrane.

### 2.6 Structural Insights from Cryo-EM

High-resolution cryo-electron microscopy (cryo-EM) structures of the full-length human GABAB receptor heterodimer (PDB: 7C7S) have provided atomic-level details of the GABBR1-GABBR2 interface. The structures reveal that the heterodimer adopts a symmetric arrangement in the extracellular domain but an asymmetric arrangement in the transmembrane domain. Upon GABA binding to GABBR1, the VFT domains undergo a closed-to-open conformational change that is transmitted through the CRD to the 7TM domains, leading to a reorientation of the GABBR2 7TM domain and exposure of the G-protein-coupling interface. This conformational coupling mechanism explains why GABBR2 is essential for G-protein activation despite not binding the orthosteric ligand.

### 2.7 Interactive 3D Visualization

For a comprehensive exploration of the GABBR2 protein structure, including domain boundaries, ligand-binding pockets, and pathogenic mutation sites, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load GABBR2 (PDB: 7C7S)](/tools/protein-structure-viewer?source=alphafold&accession=O75899)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 GABAB Receptor Heterodimerization

GABAB receptors function as obligate heterodimers composed of GABBR1 and GABBR2. Neither subunit can form a functional receptor on its own. GABBR1 contains the orthosteric binding site for GABA and the clinically used agonist baclofen, while GABBR2 is responsible for G-protein coupling and signal transduction. The heterodimerization is mediated primarily by the coiled-coil interaction in the C-terminal domains, but additional contacts in the VFT and CRD domains stabilize the complex. The assembly of the heterodimer occurs in the ER, where the coiled-coil interaction masks ER retention signals (an RXR motif in GABBR1 and an RR motif in GABBR2), allowing the complex to exit the ER and traffic to the cell surface [<a href="#ref-2">2</a>].

### 3.2 G-Protein Signaling Cascade

Upon GABA binding to GABBR1, the conformational change is transmitted to GABBR2, which catalyzes the exchange of GDP for GTP on the Gαi/o subunit of heterotrimeric G-proteins. The activated Gαi/o subunit dissociates from the Gβγ dimer, and both moieties mediate downstream effects:

1. **Inhibition of adenylyl cyclase**: Gαi directly inhibits adenylyl cyclase isoforms I, V, and VI, reducing cAMP production and decreasing protein kinase A (PKA) activity. This pathway modulates gene expression, ion channel activity, and neurotransmitter synthesis.

2. **Modulation of voltage-gated calcium channels (VGCCs)**: The Gβγ dimer directly binds to and inhibits N-type (Cav2.2) and P/Q-type (Cav2.1) calcium channels at presynaptic terminals. This reduces calcium influx and inhibits neurotransmitter release, providing a mechanism for presynaptic inhibition.

3. **Activation of G-protein-coupled inwardly rectifying potassium (GIRK) channels**: Gβγ also directly activates GIRK channels (Kir3.1/3.2 heterotetramers), increasing potassium conductance and hyperpolarizing the postsynaptic membrane. This produces the slow inhibitory postsynaptic potential (IPSP) characteristic of GABAB receptor activation.

4. **Activation of mitogen-activated protein kinase (MAPK) pathways**: Gβγ can activate the Ras-Raf-MEK-ERK cascade through the recruitment of Src family kinases and phosphatidylinositol 3-kinase (PI3K). This pathway is particularly important in the context of neuronal plasticity and long-term potentiation (LTP).

### 3.3 Regulation by Auxiliary Subunits

The signaling properties of GABAB receptors are modulated by auxiliary subunits of the KCTD (potassium channel tetramerization domain) family, including KCTD8, KCTD12, KCTD12b, and KCTD16. These proteins bind to the C-terminal domain of GABBR2 and alter the kinetics of G-protein coupling. KCTD12, for example, accelerates the onset of desensitization and slows the recovery from desensitization, while KCTD16 enhances the coupling efficiency to GIRK channels. The expression of KCTD proteins is regulated by lithium and glycogen synthase kinase-3 (GSK-3) signaling, providing a link between mood stabilizers and GABAB receptor function [<a href="#ref-3">3</a>].

### 3.4 Protein-Protein Interaction Network

The GABAB receptor interacts with a wide array of intracellular proteins beyond the G-protein subunits and KCTD proteins. Key interactors include:

- **14-3-3 proteins**: Bind to phosphorylated Ser892 in the GABBR2 CTD and stabilize the receptor at the plasma membrane.
- **GB1a/GB1b isoforms**: GABBR1 exists in two major splice variants (GB1a and GB1b) that differ in their N-terminal sushi domains. These isoforms confer differential subcellular localization, with GB1a-containing receptors enriched at presynaptic terminals and GB1b-containing receptors enriched at postsynaptic densities.
- **APP (amyloid precursor protein)**: Direct interaction between GABBR2 and APP has been demonstrated, and this interaction is disrupted in Alzheimer's disease, contributing to synaptic dysfunction [<a href="#ref-4">4</a>].
- **TRPM8/TRPV1**: In migraine pathophysiology, GABBR2 signaling modulates the activity of TRPM8 and TRPV1 channels through the PRKACA pathway, providing a mechanistic link between GABAergic signaling and pain perception [<a href="#ref-1">1</a>].

### 3.5 Signaling in Non-Neuronal Tissues

While GABAB receptors are most abundant in the CNS, they are also expressed in peripheral tissues, including pancreatic β-cells, where they regulate insulin secretion. In human pancreatic β-cell lines and islets, GABAB receptor activation inhibits glucose-stimulated insulin secretion through the Gi/o-mediated inhibition of adenylyl cyclase and reduction of cAMP levels [<a href="#ref-2">2</a>]. This peripheral function has implications for metabolic disorders and diabetes.

### 3.6 Signaling Diagram

```mermaid
sequenceDiagram
    participant GABA as "GABA"
    participant GB1 as "GABBR1 (VFT domain)"
    participant GB2 as "GABBR2 (7TM domain)"
    participant G as "Gi/o heterotrimer"
    participant AC as "Adenylyl Cyclase"
    participant GIRK as "GIRK Channel"
    participant VGCC as "Voltage-Gated Ca2+ Channel"
    participant ERK as "MAPK/ERK Pathway"
    GABA->>GB1: Binds orthosteric site
    GB1->>GB2: Conformational change via CRD
    GB2->>G: Catalyzes GDP→GTP exchange
    G->>AC: Gαi inhibits AC
    AC-->>GIRK: Reduced cAMP/PKA
    G->>GIRK: Gβγ activates GIRK
    GIRK-->>VGCC: Membrane hyperpolarization
    G->>VGCC: Gβγ inhibits VGCC
    VGCC-->>ERK: Reduced Ca2+ influx
    Note over GIRK,ERK: Slow IPSP & reduced neurotransmitter release
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Early-Infantile Epileptic Encephalopathy 59 (EIEE59)

*GABBR2* mutations are a well-established cause of EIEE59 (OMIM #617904), a severe neurodevelopmental disorder characterized by early-onset seizures, developmental regression, hypotonia, and poor prognosis. The majority of pathogenic variants are *de novo* missense mutations, although truncating and splice-site mutations have also been reported. Functional studies of these variants have revealed diverse mechanisms of pathogenicity, including loss of receptor function, dominant-negative effects, and gain-of-function alterations [1, 2].

### 4.2 Rett Syndrome-Like Phenotypes

Rett syndrome (RTT) is classically caused by mutations in *MECP2*, but a subset of patients with RTT-like phenotypes carry mutations in *GABBR2*. A landmark study identified multiple *de novo* *GABBR2* mutations in patients with RTT and epileptic encephalopathy, demonstrating that *GABBR2* mutations can phenotypically mimic RTT [<a href="#ref-1">1</a>]. The clinical features include loss of acquired skills, stereotypic hand movements, impaired language, and seizures. The phenotypic overlap between *GABBR2*-related disorders and *MECP2*-related RTT suggests convergent pathogenic mechanisms involving synaptic dysfunction and altered neuronal network activity. Transcriptomic analysis of RTT patient-derived iPSCs and neurons has revealed that *GABBR2* expression is dysregulated, further supporting its involvement in RTT pathophysiology [<a href="#ref-3">3</a>].

### 4.3 Autism Spectrum Disorder (ASD)

A de novo *GABBR2* variant linked to ASD has been functionally characterized, revealing that the mutation impairs receptor trafficking and signaling [<a href="#ref-4">4</a>]. The variant, located in the VFT domain, disrupts the folding of the protein and leads to ER retention. This loss-of-function mechanism is consistent with the hypothesis that reduced GABAergic inhibition contributes to the excitation/inhibition imbalance observed in ASD. Sex-aware genome-wide assessment of de novo variants in autism has identified *GABBR2* as a candidate risk gene, with enrichment of variants in both coding and noncoding regions [1, 2].

### 4.4 Epilepsy and Seizure Disorders

Beyond EIEE59, *GABBR2* variants have been associated with more common forms of epilepsy. A study of mesial temporal lobe epilepsy in a Han Chinese population found significant associations between *GABBR2* polymorphisms and disease susceptibility [<a href="#ref-3">3</a>]. Additionally, a constitutively active *GABBR2* variant has been shown to normalize network activity in an epilepsy model, suggesting that gain-of-function mutations may also contribute to epilepsy pathophysiology [<a href="#ref-4">4</a>]. The therapeutic potential of positive allosteric modulators (PAMs) for *GABBR2* variants has been demonstrated in vitro, where PAMs reversed presynaptic hyperexcitability caused by an epilepsy-associated variant [1, 2].

### 4.5 Intellectual Disability and Developmental Delay

Trio-based exome sequencing has identified *GABBR2* mutations in patients with isolated syndromic intellectual disability [<a href="#ref-3">3</a>]. These patients present with moderate to severe intellectual disability, delayed motor milestones, and speech impairment, often without overt seizures. The identification of *GABBR2* mutations in this context expands the phenotypic spectrum associated with this gene.

### 4.6 Schizophrenia

Gene prioritization analyses for schizophrenia have identified *GABBR2* as a potential drug target [<a href="#ref-4">4</a>]. The GABAergic hypothesis of schizophrenia posits that reduced GABAergic transmission contributes to the cognitive and negative symptoms of the disorder. Genetic association studies have reported associations between *GABBR2* polymorphisms and treatment-resistant schizophrenia, suggesting that *GABBR2* may modulate antipsychotic response [<a href="#ref-1">1</a>].

### 4.7 Migraine

Genetic association studies have investigated the role of *GABBR2* polymorphisms in migraine susceptibility. A case-control study in a Turkish population examined the association between rs230416 and rs230429 and migraine with aura, finding significant associations [<a href="#ref-2">2</a>]. Additionally, gene expression studies have shown that *GABBR2* is differentially expressed in peripheral blood leukocytes of migraineurs compared to controls [<a href="#ref-3">3</a>]. The involvement of *GABBR2* in migraine pathophysiology is further supported by studies showing that the combination of paeonol and glycyrrhizic acid ameliorates migraine-like phenotypes in rats by regulating the GABBR2/TRPM8/PRKACA/TRPV1 pathway [<a href="#ref-1">1</a>].

### 4.8 Huntington's Disease

A *GABBR2* gene variant has been shown to modify pathophysiology in Huntington's disease (HD) [<a href="#ref-4">4</a>]. The variant, rs230416, was associated with altered age at onset and disease progression in HD patients. This modifying effect is likely mediated through changes in GABAergic transmission, which is known to be impaired in HD.

### 4.9 Substance Use Disorders

*GABBR2* has been extensively studied in the context of substance use disorders. Genetic association studies have linked *GABBR2* polymorphisms to nicotine dependence in European- and African-American populations [1, 2]. A study of alcohol-dependent individuals found that *GABBR2* variants affect cigarette smoking patterns [<a href="#ref-3">3</a>]. Additionally, *GABBR2* haplotypes have been associated with alcohol use disorder in an Italian sample [<a href="#ref-4">4</a>]. The role of *GABBR2* in substance use is supported by animal studies showing altered *Gabbr2* expression in the hippocampus and striatum of heroin-treated monkeys [<a href="#ref-1">1</a>] and in rats with alcohol-seeking behavior [<a href="#ref-2">2</a>].

### 4.10 Obstructive Sleep Apnea Syndrome (OSAS)

Evidence of association between *GABBR2* gene polymorphisms and obstructive sleep apnea syndrome has been reported in asthma patients [3, 4]. The GABAergic system is involved in the regulation of upper airway muscle tone and respiratory drive, and genetic variation in *GABBR2* may contribute to the pathogenesis of OSAS.

### 4.11 Alzheimer's Disease

*GABBR2* has been identified as a diagnostic marker for Alzheimer's disease (AD), with expression levels associated with Aβ pathology [<a href="#ref-4">4</a>]. The interaction between GABBR2 and amyloid precursor protein (APP) suggests a direct role in AD pathophysiology. Additionally, deep learning models and molecular docking studies have identified *GABBR2* as a potential therapeutic target for AD [<a href="#ref-1">1</a>].

### 4.12 Cancer

*GABBR2* expression is dysregulated in multiple cancer types. In prostate cancer, miR-31-3p functions as a tumor suppressor by directly targeting *GABBR2*, and reduced miR-31-3p expression leads to increased *GABBR2* levels that promote tumorigenesis [<a href="#ref-1">1</a>]. In lung adenocarcinoma, *GABBR2* promoter methylation is associated with response to erlotinib treatment [<a href="#ref-2">2</a>]. *GABBR2* has also been implicated in colorectal cancer, where GABA pathway gene expression impacts first-line treatment outcomes [<a href="#ref-2">2</a>]. The role of *GABBR2* in cancer is likely mediated through its effects on cell proliferation, migration, and apoptosis, although the precise mechanisms remain to be fully elucidated.

### 4.13 Pathogenic Variant Table

| **Variant** | **Protein Change** | **Domain** | **Phenotype** | **Mechanism** | **Reference** |
|---|---|---|---|---|---|
| c.2366C>T | p.A789V | 7TM | EIEE59 | Loss of G-protein coupling | [<a href="#ref-1">1</a>] |
| c.129G>A | p.C129Y | VFT | EIEE59 | Disrupted disulfide bond, ER retention | [<a href="#ref-1">1</a>] |
| c.2545A>G | p.S849G | CTD | RTT-like | Impaired trafficking | [<a href="#ref-1">1</a>] |
| c.1699G>A | p.V567M | CRD | ASD | Impaired receptor function | [<a href="#ref-4">4</a>] |
| c.2264T>C | p.L755P | 7TM | EIEE59 | Loss of function | [<a href="#ref-3">3</a>] |
| c.1780C>T | p.R594W | 7TM | Epilepsy | Gain of function | [<a href="#ref-4">4</a>] |
| rs230416 | Intronic | - | Migraine, HD modifier | Altered splicing/expression | [2, 4] |
| rs230429 | Intronic | - | Migraine | Altered splicing/expression | [<a href="#ref-2">2</a>] |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Herpes Simplex Virus Type 1 (HSV-1)

HSV-1 establishes lifelong latent infections in sensory neurons, and its latency-associated transcript (LAT) encodes several microRNAs, including miR-H3 and miR-H4. These viral miRNAs have been shown to target the *STXBP1* and *GABBR2* genes [<a href="#ref-4">4</a>]. By downregulating *GABBR2* expression, HSV-1 may modulate GABAergic signaling in infected neurons, potentially contributing to the neurological complications associated with HSV-1 encephalitis and to the maintenance of viral latency. The targeting of *GABBR2* by viral miRNAs represents a novel mechanism of host-pathogen interaction whereby a neurotropic virus directly manipulates inhibitory neurotransmission.

### 5.2 Implications for Viral Encephalitis

The downregulation of *GABBR2* by HSV-1 miRNAs could lead to reduced GABAergic inhibition and increased neuronal excitability. This may contribute to the seizure activity observed in HSV-1 encephalitis. Additionally, altered GABAergic signaling may affect the immune response to the virus, as GABA has been shown to modulate neuroinflammation. The interaction between HSV-1 and *GABBR2* highlights the vulnerability of the GABAergic system to viral manipulation and suggests that GABAB receptor modulators could have therapeutic potential in viral encephalitis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Orthosteric Agonists

**Baclofen** is the prototypical GABAB receptor agonist and is FDA-approved for the treatment of spasticity. It binds to the orthosteric site in the GABBR1 VFT domain, and its efficacy requires the presence of GABBR2 for G-protein coupling. Baclofen has also been investigated for the treatment of alcohol use disorder, where it has shown efficacy in reducing alcohol consumption and craving. The therapeutic effects of baclofen are mediated through GABAB receptor activation, which requires functional GABBR2.

### 6.2 Positive Allosteric Modulators (PAMs)

PAMs bind to the 7TM domain of GABBR2 and enhance the response to orthosteric agonists without directly activating the receptor. Several PAMs have been developed, including:

- **GS39783**: Enhances GABAB receptor signaling and has shown anxiolytic and antidepressant-like effects in animal models.
- **rac-BHFF**: A potent PAM that enhances GABA potency and efficacy.
- **CGP7930**: A PAM that also has weak agonist activity at high concentrations.

PAMs have therapeutic potential for conditions associated with reduced GABAergic function, including epilepsy, anxiety, depression, and substance use disorders. In the context of *GABBR2* mutations that cause loss of function, PAMs could potentially rescue receptor signaling. A study demonstrated that a PAM reversed presynaptic hyperexcitability caused by a GABABR epilepsy variant, suggesting that PAMs may be effective in treating *GABBR2*-related epilepsies [1, 2].

### 6.3 Negative Allosteric Modulators (NAMs)

NAMs inhibit GABAB receptor signaling and have potential therapeutic applications in conditions associated with excessive GABAergic inhibition, such as cognitive disorders and certain forms of epilepsy. The development of NAMs targeting GABBR2 is an active area of research, although no NAMs have yet received regulatory approval.

### 6.4 Antagonists

**CGP54626** and **CGP55845** are high-affinity GABAB receptor antagonists that bind to the orthosteric site in GABBR1. These compounds are used primarily as research tools to study GABAB receptor function. They have no clinical applications due to their pro-convulsant and cognitive-impairing effects.

### 6.5 Gene Therapy Approaches

The identification of *GABBR2* mutations as a cause of EIEE59 and RTT-like phenotypes has prompted interest in gene therapy approaches. Adeno-associated virus (AAV) vectors encoding the wild-type *GABBR2* cDNA could potentially be used to restore receptor function in patients with loss-of-function mutations. However, the large size of the *GABBR2* coding sequence (~2.7 kb) is compatible with AAV packaging, making this approach technically feasible. Preclinical studies in animal models will be necessary to evaluate the safety and efficacy of this approach.

### 6.6 Pharmacogenomic Considerations

Genetic variation in *GABBR2* may influence the response to GABAB receptor-targeted drugs. For example, polymorphisms that affect receptor expression or function could alter the efficacy of baclofen or PAMs. Pharmacogenomic studies are needed to determine whether *GABBR2* genotyping can guide drug selection and dosing. Additionally, the epigenetic regulation of *GABBR2* expression may influence drug response, as demonstrated by the association between *GABBR2* promoter methylation and erlotinib response in lung adenocarcinoma [<a href="#ref-2">2</a>].

### 6.7 Drug Repurposing

The involvement of *GABBR2* in multiple conditions has prompted drug repurposing efforts. For example, baclofen is being investigated for the treatment of alcohol use disorder, and PAMs are being evaluated for the treatment of epilepsy and neuropathic pain. The combination of paeonol and glycyrrhizic acid, which regulate the GABBR2/TRPM8/PRKACA/TRPV1 pathway, has shown efficacy in a rat model of migraine [<a href="#ref-1">1</a>]. These repurposing efforts leverage the central role of GABBR2 in modulating neuronal excitability and neurotransmitter release.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 4507 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4507 |
| NCBI Gene | 9568 | https://www.ncbi.nlm.nih.gov/gene/9568 |
| Ensembl | ENSG00000136928 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136928 |
| UniProt | O75899 | https://www.uniprot.org/uniprotkb/O75899/entry |
| RCSB PDB | 7C7S | https://www.rcsb.org/structure/7C7S |
| OMIM | 607340 (GABBR2), 617904 (EIEE59) | https://www.omim.org/entry/607340 |
| ClinVar | GABBR2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=GABBR2%5Bgene%5D |
| GTEx | GABBR2 | https://gtexportal.org/home/gene/GABBR2 |
| STRING | O75899 | https://string-db.org/network/9606.ENSP00000258423 |
| BioGRID | 120694 | https://thebiogrid.org/120694 |
| Gene Ontology (GO) | GO:0004930 (GPCR activity), GO:0007186 (G-protein-coupled receptor signaling), GO:0004965 (GABA-B receptor activity) | https://www.ebi.ac.uk/QuickGO/ |
| PharmGKB | GABBR2 | https://www.pharmgkb.org/gene/PA28474 |
| Human Protein Atlas | ENSG00000136928 | https://www.proteinatlas.org/ENSG00000136928-GABBR2 |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0004965 | GABA-B receptor activity |
| Molecular Function | GO:0004930 | G protein-coupled receptor activity |
| Molecular Function | GO:0031683 | G-protein beta/gamma-subunit complex binding |
| Biological Process | GO:0007186 | G protein-coupled receptor signaling pathway |
| Biological Process | GO:0007214 | Gamma-aminobutyric acid signaling pathway |
| Biological Process | GO:0060079 | Excitatory postsynaptic potential |
| Biological Process | GO:0060080 | Inhibitory postsynaptic potential |
| Biological Process | GO:0007268 | Chemical synaptic transmission |
| Cellular Component | GO:0005886 | Plasma membrane |
| Cellular Component | GO:0045202 | Synapse |
| Cellular Component | GO:0030424 | Axon |
| Cellular Component | GO:0043025 | Neuronal cell body |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Hens JR, Brown S, Licznerski P, Suarez J, Jonas E, Wysolmerski JJ. Development of a floxed Gabbr2 gene allows for widespread conditional disruption of GABBR2 and recapitulates the phenotype of germline Gabbr2 knockout mice. bioRxiv. 2025. https://www.semanticscholar.org/paper/12c20309dd0a5da245d1a92e8a55792b3f162c5b

<a id="ref-2"></a>[2] Özdemir E, Tatar A, Ozdemir G. Evaluation of GABBR2 gene polymorphisms rs230416 and rs230429 in migraine with aura: A case-control study in a Turkish population. Türk Nöroloji Dergisi. 2026. https://www.semanticscholar.org/paper/375d78df7a2baf2e509c25656042dcd2c12dbe8e

<a id="ref-3"></a>[3] Philpott AL, Fitzgerald P, Bailey N, Churchyard A, Georgiou-Karistianis N, Cummins TDR. A GABBR2 gene variant modifies pathophysiology in Huntington's disease. Neuroscience Letters. 2016. https://www.semanticscholar.org/paper/94669d74aa3f9796ea0d41e3a8e40211e1e6c3ba

<a id="ref-4"></a>[4] Sheludko E, Kotova O, Perelman J, Kolosov V, Wong K, Yee B, Wang D, Grunstein R, Piper A. Evidence of association between GABBR2 gene polymorphism and obstructive sleep apnea syndrome in asthma patients.